Clinical manifestations in patients with alpha-fetoprotein-producing gastric cancer

H. J. Lin, Y. H. Hsieh, W. L. Fang, K. H. Huang, A. F Y Li

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background Patients with alpha-fetoprotein (afp)-producing gastric cancer have a high incidence of liver metastasis and poor prognosis. There is some controversy about clinical manifestations in these patients. Methods Our study enrolled patients who, before surgery, had gastric cancer with serum afp exceeding 20 ng/mL [AFP>20 (n = 58)] and with serum AFP 20 ng/mL or less [AFP≤20 (n = 1236)]. Clinical manifestations were compared between the groups. prognosis. More aggressive management with mul-timodal therapy (for example, chemotherapy, radiotherapy) might be needed when treating such patients. Results Early gastric cancer was more frequent (30.1% vs. 4%) and advanced gastric cancer was less frequent (69.9% vs. 96%) in the AFP≤20 group than the AFP>20 group (p <0.001). Liver and lymph node metastasis occurred less frequently in the AFP≤20 group (4.4% vs. 27.6%, p <0.001, and 60.7% vs. 91.4%, p <0.001, respectively). The 1-, 3-, 5-, and 10-year survival rates of AFP≤20 patients were 75.2%, 53.4%, 45.8%, and 34.6% respectively. The 1-, 3-, 5-, and 10-year survival rates of patients with AFP greater than 20 ng/mL, but 300 ng/ mL or less, were 46.7%, 28.9%, 17.8%, and 13.3% respectively. The 1-, 3-, and 5-year survival rates of patients with serum AFP greater than 300 ng/mL were 15.4%, 7.7%, and 0% respectively. The independent predictors for survival time were AFP concentration, age, peritoneal seeding, liver metastasis, lymph node metastasis, vascular invasion, TNM stage, curative surgery, serosal invasion, and Lauren classification. Conclusions Patients with high serum AFP had a high frequency of liver and lymph node metastasis and very poor prognosis. More aggressive management with multimodal therapy (for example, chemotherapy, radiotherapy) might be needed when treating such patients.

Original languageEnglish
Pages (from-to)394-399
Number of pages6
JournalCurrent Oncology
Volume21
Issue number3
DOIs
Publication statusPublished - 2014

Fingerprint

alpha-Fetoproteins
Stomach Neoplasms
Neoplasm Metastasis
Survival Rate
Lymph Nodes
Liver
Serum
Radiotherapy
Drug Therapy
Blood Vessels
Survival
Incidence
Therapeutics

Keywords

  • Alpha-fetoprotein
  • Early gastric cancer
  • Gastric cancer
  • Metastasis

ASJC Scopus subject areas

  • Oncology

Cite this

Clinical manifestations in patients with alpha-fetoprotein-producing gastric cancer. / Lin, H. J.; Hsieh, Y. H.; Fang, W. L.; Huang, K. H.; Li, A. F Y.

In: Current Oncology, Vol. 21, No. 3, 2014, p. 394-399.

Research output: Contribution to journalArticle

Lin, H. J. ; Hsieh, Y. H. ; Fang, W. L. ; Huang, K. H. ; Li, A. F Y. / Clinical manifestations in patients with alpha-fetoprotein-producing gastric cancer. In: Current Oncology. 2014 ; Vol. 21, No. 3. pp. 394-399.
@article{41a8b5568b544f8bad02e356cb7da2de,
title = "Clinical manifestations in patients with alpha-fetoprotein-producing gastric cancer",
abstract = "Background Patients with alpha-fetoprotein (afp)-producing gastric cancer have a high incidence of liver metastasis and poor prognosis. There is some controversy about clinical manifestations in these patients. Methods Our study enrolled patients who, before surgery, had gastric cancer with serum afp exceeding 20 ng/mL [AFP>20 (n = 58)] and with serum AFP 20 ng/mL or less [AFP≤20 (n = 1236)]. Clinical manifestations were compared between the groups. prognosis. More aggressive management with mul-timodal therapy (for example, chemotherapy, radiotherapy) might be needed when treating such patients. Results Early gastric cancer was more frequent (30.1{\%} vs. 4{\%}) and advanced gastric cancer was less frequent (69.9{\%} vs. 96{\%}) in the AFP≤20 group than the AFP>20 group (p <0.001). Liver and lymph node metastasis occurred less frequently in the AFP≤20 group (4.4{\%} vs. 27.6{\%}, p <0.001, and 60.7{\%} vs. 91.4{\%}, p <0.001, respectively). The 1-, 3-, 5-, and 10-year survival rates of AFP≤20 patients were 75.2{\%}, 53.4{\%}, 45.8{\%}, and 34.6{\%} respectively. The 1-, 3-, 5-, and 10-year survival rates of patients with AFP greater than 20 ng/mL, but 300 ng/ mL or less, were 46.7{\%}, 28.9{\%}, 17.8{\%}, and 13.3{\%} respectively. The 1-, 3-, and 5-year survival rates of patients with serum AFP greater than 300 ng/mL were 15.4{\%}, 7.7{\%}, and 0{\%} respectively. The independent predictors for survival time were AFP concentration, age, peritoneal seeding, liver metastasis, lymph node metastasis, vascular invasion, TNM stage, curative surgery, serosal invasion, and Lauren classification. Conclusions Patients with high serum AFP had a high frequency of liver and lymph node metastasis and very poor prognosis. More aggressive management with multimodal therapy (for example, chemotherapy, radiotherapy) might be needed when treating such patients.",
keywords = "Alpha-fetoprotein, Early gastric cancer, Gastric cancer, Metastasis",
author = "Lin, {H. J.} and Hsieh, {Y. H.} and Fang, {W. L.} and Huang, {K. H.} and Li, {A. F Y}",
year = "2014",
doi = "10.3747/co.21.1768",
language = "English",
volume = "21",
pages = "394--399",
journal = "Current Oncology",
issn = "1198-0052",
publisher = "Multimed Inc.",
number = "3",

}

TY - JOUR

T1 - Clinical manifestations in patients with alpha-fetoprotein-producing gastric cancer

AU - Lin, H. J.

AU - Hsieh, Y. H.

AU - Fang, W. L.

AU - Huang, K. H.

AU - Li, A. F Y

PY - 2014

Y1 - 2014

N2 - Background Patients with alpha-fetoprotein (afp)-producing gastric cancer have a high incidence of liver metastasis and poor prognosis. There is some controversy about clinical manifestations in these patients. Methods Our study enrolled patients who, before surgery, had gastric cancer with serum afp exceeding 20 ng/mL [AFP>20 (n = 58)] and with serum AFP 20 ng/mL or less [AFP≤20 (n = 1236)]. Clinical manifestations were compared between the groups. prognosis. More aggressive management with mul-timodal therapy (for example, chemotherapy, radiotherapy) might be needed when treating such patients. Results Early gastric cancer was more frequent (30.1% vs. 4%) and advanced gastric cancer was less frequent (69.9% vs. 96%) in the AFP≤20 group than the AFP>20 group (p <0.001). Liver and lymph node metastasis occurred less frequently in the AFP≤20 group (4.4% vs. 27.6%, p <0.001, and 60.7% vs. 91.4%, p <0.001, respectively). The 1-, 3-, 5-, and 10-year survival rates of AFP≤20 patients were 75.2%, 53.4%, 45.8%, and 34.6% respectively. The 1-, 3-, 5-, and 10-year survival rates of patients with AFP greater than 20 ng/mL, but 300 ng/ mL or less, were 46.7%, 28.9%, 17.8%, and 13.3% respectively. The 1-, 3-, and 5-year survival rates of patients with serum AFP greater than 300 ng/mL were 15.4%, 7.7%, and 0% respectively. The independent predictors for survival time were AFP concentration, age, peritoneal seeding, liver metastasis, lymph node metastasis, vascular invasion, TNM stage, curative surgery, serosal invasion, and Lauren classification. Conclusions Patients with high serum AFP had a high frequency of liver and lymph node metastasis and very poor prognosis. More aggressive management with multimodal therapy (for example, chemotherapy, radiotherapy) might be needed when treating such patients.

AB - Background Patients with alpha-fetoprotein (afp)-producing gastric cancer have a high incidence of liver metastasis and poor prognosis. There is some controversy about clinical manifestations in these patients. Methods Our study enrolled patients who, before surgery, had gastric cancer with serum afp exceeding 20 ng/mL [AFP>20 (n = 58)] and with serum AFP 20 ng/mL or less [AFP≤20 (n = 1236)]. Clinical manifestations were compared between the groups. prognosis. More aggressive management with mul-timodal therapy (for example, chemotherapy, radiotherapy) might be needed when treating such patients. Results Early gastric cancer was more frequent (30.1% vs. 4%) and advanced gastric cancer was less frequent (69.9% vs. 96%) in the AFP≤20 group than the AFP>20 group (p <0.001). Liver and lymph node metastasis occurred less frequently in the AFP≤20 group (4.4% vs. 27.6%, p <0.001, and 60.7% vs. 91.4%, p <0.001, respectively). The 1-, 3-, 5-, and 10-year survival rates of AFP≤20 patients were 75.2%, 53.4%, 45.8%, and 34.6% respectively. The 1-, 3-, 5-, and 10-year survival rates of patients with AFP greater than 20 ng/mL, but 300 ng/ mL or less, were 46.7%, 28.9%, 17.8%, and 13.3% respectively. The 1-, 3-, and 5-year survival rates of patients with serum AFP greater than 300 ng/mL were 15.4%, 7.7%, and 0% respectively. The independent predictors for survival time were AFP concentration, age, peritoneal seeding, liver metastasis, lymph node metastasis, vascular invasion, TNM stage, curative surgery, serosal invasion, and Lauren classification. Conclusions Patients with high serum AFP had a high frequency of liver and lymph node metastasis and very poor prognosis. More aggressive management with multimodal therapy (for example, chemotherapy, radiotherapy) might be needed when treating such patients.

KW - Alpha-fetoprotein

KW - Early gastric cancer

KW - Gastric cancer

KW - Metastasis

UR - http://www.scopus.com/inward/record.url?scp=84902649133&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902649133&partnerID=8YFLogxK

U2 - 10.3747/co.21.1768

DO - 10.3747/co.21.1768

M3 - Article

AN - SCOPUS:84902649133

VL - 21

SP - 394

EP - 399

JO - Current Oncology

JF - Current Oncology

SN - 1198-0052

IS - 3

ER -